Healthy volunteers who received i.v. injections of either saline or haloperidol (0.5 or 1.0 mg) made visual analogue scale ratings of subjective mood, tension, shakiness and the global feeling of having received an active drug. The subjective ratings of volunteers who received haloperidol did not differ, overall, from those who received saline. In contrast, the drug caused clear objective changes in several psychological tests. I.v. administration of low doses of haloperidol may permit double-blind testing of the psychological actions of haloperidol in healthy volunteers.
Association of the British Pharmaceutical Industry (1986) ABPI data sheet compendium. Datapharm Publications Limited, London, pp. 1416-1419
2.
Association of the British Pharmaceutical Industry (1993) ABPI data sheet compendium. Datapharm Publications Limited, London, pp. 693-695
3.
Allan L.M., Williams J.H., Wellman N.A., Tonin J., Taylor E., Feldon J., Rawlins J N P (1995) Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Personal Ind Diff19: 893-902
4.
Anderson B.G., Reker D., Cooper T.B. (1981) Prolonged adverse effect of haloperidol in normal subjects. N Engl J Med305: 643-644
5.
Baruch I., Hemsley D.R., Gray JA ( 1988) Differential performance of acute and chronic schizophrenics on a latent inhibition task. J Nerv Ment Dis176: 598-606
6.
Chang W.H., Lam Y.W., Jann M.W., Chen H. ( 1992) Pharmacokinetics of haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology106: 515-522
7.
Chapman L.J., Chapman J.P., Kwapil T.R., Eckblad M., Zinser M.C. (1994) Putatively psychosis-prone individuals ten years on. J Abnorm Psychol103:171-183
8.
Claridge G.S., Broks P. (1985) Schizotypy and hemisphere function. I. Theoretical considerations and measurement of schizotypy. Personal Ind Diff5: 633-648
9.
Cohen J. (1977) Statistical power analysis for the behavioral sciences . Academic Press, New York
10.
Collett D. (1994) Modelling survival data in medical research, Chat-field C, Zidek JV (eds). Chapman & Hall, London
11.
Cox D.R., Oakes D. (1984) Analysis of survival data, Cox D R, Hinkley D V, et al. (eds). Chapman & Hall, London
12.
Crow TJ ( 1990) Temporal lobe asymmetries as the key to the aetiology of schizophrenia. Schizophr Bull16: 433-443
Froemming J.S., Lam Y.W., Jann M.W., Davis C.M. (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet17: 396-423
15.
Gray N.S., Pickering A.D., Hemsley D.R., Dawling S., Gray JA ( 1992) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiat Brain Res1: 83-89
16.
Gray N.S., Pilowsky L.S., Gray JA, Kerwin R.W. (1995) Abolition of latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res17: 95-107
17.
King D.J. (1994) Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiat Scand89 (Suppl. 380): 53-58
18.
King D.J., Burke M., Lucas R.A. (1995) Antipsychotic drug-induced dysphoria. Br J Psychiat167: 480-482
19.
Lipp OV, Vaitl D. (1992) Latent inhibition in human Pavlovian conditioning: effect of additional stimulation after preexposure and relation to schizotypal traits. Personal Ind Diff13: 1003-1012
20.
Lubow R.E., Ingberg-Sachs Y., Zalstein-Orda N., Gewirtz J.C. (1992) Latent inhibition in low and high psychotic-prone normal subjects. Personal Ind Diff13: 563-572
21.
Newcomer J.W., Miller L.S., Faustman W.O., Wetzel M.W., Vogler G.P., Csernansky J.G. (1994) Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. Br J Psychiat164: 834-838
22.
Nordstrom A-L., Farde L., Halldin C. (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology106: 433-438
23.
Seeman P. (1995) Dopamine receptors: clinical correlates. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: the fourth generation of progress . Raven Press, New York, pp. 295-302
24.
Spss (1993) Advanced statistics guide. SPSS, Chicago, IL
25.
Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M. (1995) Latent inhibition in schizophrenia. Schizophr Res20: 91-103
26.
Williams J.H., Wellman N.A., Rawlins J N P, Geaney D.P., Cowen PJ, Feldon J. (1994) Haloperidol increases latent inhibition in high schizotypal subjects. Schizophren Res11:162 (abstract)
27.
Williams J.H., Wellman N.A., Geaney D.P., Rawlins J N P, Feldon J., Cowen PJ (1996a) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomised controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiat40:1135-1143
28.
Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J., Rawlins J N P (1996b) Haloperidol reduces Stroop interference and increases negative priming in healthy people. Schizophr Res18: 223 (abstract)
29.
Williams J.H., Wellman N.A., Rawlins J N P (1996c) Cannabis use correlates with schizotypy in healthy people. Addiction91: 869-877
30.
Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J., Rawlins J N P (1996d) Latent inhibition is not reduced in drug-free patients with schizophrenia. Schizophr Res18: 202 (abstract)
31.
Williams J.H., Wellman N.A., Geaney D.P., Rawlins J N P, Feldon J., Cowen PJ (1997) Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology, in press
